Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma, Blood, vol.131, issue.25, pp.2856-2859, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01812478
PD-1 blockade for relapsed lymphoma postallogeneic hematopoietic cell transplant: high response rate but frequent GVHD, Blood, vol.130, issue.2, pp.221-228, 2017. ,
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma, Blood, vol.129, issue.18, pp.2471-2478, 2017. ,
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases, Cancer Chemother Pharmacol, vol.81, issue.6, pp.1105-1109, 2018. ,
Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab, Cancer Chemother Pharmacol, vol.80, issue.5, pp.999-1004, 2017. ,
Nivolumab re-treatment in patients with relapsed/refractory Hodgkin lymphoma. Presented at the 11 th International Symposium on Hodgkin Lymphoma, Abstract #0116, 2018. ,
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087, Blood, vol.134, issue.14, pp.114-1153, 2019. ,